PEG-Interferon
- TRADE NAMES: Pegasys; PegIntron (Schering); Sylatron (Schering)
- INDICATIONS: Chronic hepatitis C, melanoma
- CLASS: Immunomodulator, Interferon
- HALF-LIFE: ~40 hours
ACE inhibitors, Acetaminophen, Aldesleukin, Bupivacaine, Cilostazol, Cinacalcet, CYP2C9 substrates, CYP2D6 substrates, Delavirdine, Duloxetine, Estradiol, Fesoterodine, Fingolimod, Fluoxetine, Indinavir, Melphalan, Methadone, Methylnaltrexone, Pantoprazole, Pegloticase, Ribavirin, Sildenafil, Tapentadol, Telbivudine, Theophylline, Theophylline derivatives, Tiotropium, Trimethoprim, Voriconazole, Warfarin, Zidovudine
PREGNANCY CATEGORY: C
pregnancy category will be X when used in combination with ribavirin
PEG-interferon is commonly administered with ribavirin and many of the reactions listed below are in combination therapy with this drug.
Contra-indicated in patients with known hypersensitivity reactions, such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis to interferon alpha or any other product component; or with autoimmune hepatitis.
RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS and DEPRESSION AND OTHER NEUROPSYCHIATRIC DISORDERS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
